Track topics on Twitter Track topics that are important to you
On 11 September 2017, groups representing physicians in the US commented on the biosimilar reimbursement policy of the Centers for Medicare & Medicaid Services (CMS). The six groups, which represent a broad spectrum of physicians who prescribe biologicals, have urged the CMS to revise its policy of assigning a single code to all biosimilars. Instead they urge the CMS to adopt unique Healthcare Common Procedure Coding System (HCPCS) billing codes, otherwise known as J‑Codes.
Original Article: Physicians urge CMS to adopt unique billing codes for biosimilarsNEXT ARTICLE
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...